The FTC Is Attacking Drugmakersā āPatent Thicketsā
Itās a big job clearing out so-called āpatent thicketsā drugmakers create to keep their productsā prices high. But the Federal Trade Commission is giving it a shot.
Drugs
201-220 of 1,318 results
-
-
Ketamine Therapy for Mental Health a āWild Westā for Doctors and Patients
Ketamine, approved by the FDA as an anesthetic in 1970, is emerging as a major alternative mental health treatment, and there are now more than 500 ketamine clinics around the country. But with little regulation and widely varying treatment protocols, itās a medical "wild West."
By Dawn Megli -
Records Show Publix Opioid Sales Grew Even as Addiction Crisis Prompted Other Chainsā Pullback
As national prescription drug distributors and pharmacies restricted the flow of oxycodone and other painkillers in response to the growing opioid crisis, Floridaās most popular grocery store ramped up its sales and distribution of the highly addictive drugs, according to a Tampa Bay Times analysis of federal data.
Health Enters the Presidential Race
Episode 331New Hampshire voters have spoken, and it seems increasingly clear that this Novemberās election will pit President Joe Biden against former President Donald Trump. Both appear to be making health a key part of their campaigns, with Trump vowing (again) to repeal the Affordable Care Act, and Biden stressing his support for contraception and abortion rights. Meanwhile, both candidates will try to highlight efforts to rein in prescription drug prices. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Jessie Hellmann of CQ Roll Call join Ńī¹óåś“«Ć½Ņīl Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Sarah Somers of the National Health Law Program about the potential consequences for the health care system if the Supreme Court overturns a key precedent attempting to balance executive vs. judicial power.
-
-
What the Health Care Sector Was Selling at the J.P. Morgan Confab
When bankers and investors flocked to San Francisco for the largest gathering of health care industry investors, the buzz was all about artificial intelligence, the next hit weight-loss drug, and new opportunities to make money through nonprofit hospitals.
By Molly Castle Work and Arthur Allen -
Journalist Talks Distribution of Opioid Funds ā And the Companies Angling for a Piece
Ńī¹óåś“«Ć½Ņīl Health News senior correspondent Aneri Pattani made the rounds on national and local media in the last two weeks to discuss the opioid settlement funds flowing to state and local governments and her reporting on the topic. Hereās a collection of her appearances.
-
Trump Official Who OKād Drugs From Canada Chairs Company Behind Floridaās Import Plan
Alex Azar advanced Canadian drug importation as Donald Trumpās secretary of Health and Human Services. Now he chairs the board of a company managing Floridaās importation program.
-
-
Journalists Track Medical Device Malfunctions, Opioid Settlement Payments, and Abortion Bans
Ńī¹óåś“«Ć½Ņīl Health News and California Healthline staffers made the rounds on national and local media this week to discuss their stories. Hereās a collection of their appearances.
-
Patients With Narcolepsy Face a Dual Nightmare of Medication Shortages and Stigma
It's been more than a year since the FDA declared a national shortage of Adderall, and itās affecting more than just patients with ADHD. Those with narcolepsy, a much rarer condition, are often treated with the same medication. Without it, they're often unable to drive or function as usual.
2023 Is a Wrap
Episode 3272023 was another busy year in health care. As the covid-19 pandemic waned, policymakers looked anew at long-standing obstacles to obtaining and paying for care in the nationās health care system. Meanwhile, abortion has continued to be an issue in much of the nation, as states respond to the Supreme Courtās 2022 decision overturning the constitutional right to the procedure. This week, Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico Magazine join Ńī¹óåś“«Ć½Ņīl Health News chief Washington correspondent Julie Rovner to discuss these issues and wrap up the year in health. Also this week, Rovner interviews Ńī¹óåś“«Ć½Ņīl Health Newsā Jordan Rau about his joint Ńī¹óåś“«Ć½Ņīl Health News-New York Times series āDying Broke.ā
-
The Year in Opioid Settlements: 5 Things You Need to Know
In the past year, opioid settlement money has gone from an emerging funding stream for which people had lofty but uncertain aspirations to a coveted pot of billions being invested in remediation efforts. Here are some important and evolving factors to watch going forward.
-
A New Test Could Save Arthritis Patients Time, Money, and Pain. But Will It Be Used?
Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.
By Arthur Allen -
-
-
Colorado Blames Biden Team and Drugmakers for Delaying Canadian Imports
Colorado officials say they havenāt been able to stand up a program to import drugs from Canada because of drugmaker opposition ā and the Biden administrationās inaction.
-
These Programs Put Unused Prescription Drugs in the Hands of Patients in Need
States and counties look to expand programs that accept donations of unused surplus drugs from places like nursing homes and hospitals and redistribute them to low-income and uninsured residents.
By Kate Ruder -
Readers Slam Hospital Monopolies and Blame the Feds for Understaffed Nursing Homes
Ńī¹óåś“«Ć½Ņīl Health News gives readers a chance to comment on a recent batch of stories.
-
Watch and Listen: Opioid Settlement Case Triggers Protests Outside the High Court
The Supreme Court heard arguments over whether the Sacklers, the family behind Purdue Pharma ā which marketed OxyContin ā could claim immunity from future lawsuits without claiming bankruptcy.